Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRUNELLO: Remigromig vs Ranibizumab in Diabetic Macular Edema
NCT06571045Phase 3Active, not recruiting
- Sponsor
- EyeBio
- Start
- Aug 2024
- Primary completion
- Jul 2026
- Modality
- Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in diabetic macular edema (DME) (3 arms), sponsored by EyeBio. Primary endpoint: Change from baseline in Best-Corrected Visual Acuity at 52 weeks. Started Aug 2024; status: active, not recruiting.
02
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06571045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06571045.